Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
- Successor Expected to be Announced Shortly -
In
"Dan has taken ImmunoGen from being a research company with a validated
technology to one with strong research, development, clinical and
manufacturing functions that is advancing a rich pipeline of product
candidates driven by an expanding technology portfolio," commented
"For over seven years, I have had the privilege of leading a company
full of smart, team-oriented employees committed to developing better
treatments for cancer," noted
About
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is in Phase 2 testing for the treatment of folate receptor α-positive ovarian cancer. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
View source version on businesswire.com: http://www.businesswire.com/news/home/20160405005301/en/
For Investors:
info@immunogen.com
or
For
Media:
michael@michaellampeconsulting.com
Source:
News Provided by Acquire Media